HPV VaccinationNCT07648953
Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors
A study testing Microvideos: HPV Vaccination Education in people with HPV Vaccination, run by University of Utah at 1 site in United States.
Trial summary
This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic… Read more about this study
- Who is it for?
- Ages 18 to 26 years
- Conditions the study is for
- HPV Vaccination
- What is being tested?
- Microvideos: HPV Vaccination Education
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteUnited States
- Study dates
- 27 Oct 2026to May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 26 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.
- Currently use Facebook or willing to create a Facebook account to use for the duration of the study.
- At the time of enrollment, have not completed all recommended doses of the HPV vaccine.
Who cannot join
- Unable to speak and understand English.
- Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.
- Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Utah
Salt Lake City, Utah, 84112
Echo Warner, MPH, PhD, SB, 801-244-7040, echo.warner@hci.utah.edu
Echo Warner, MPH, PhD, SB
About this study
This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.
Understanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.
- Conditions
- HPV Vaccination
- Being tested
- Microvideos: HPV Vaccination Education
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Microvideos: HPV Vaccination EducationBehavioural
To educate survivors of childhood cancers about a key cancer prevention strategy, HPV vaccination. The core microvideos will focus on the 5 Ws of HPV vaccination: Who should get vaccinated, What HPV vaccination protects against, When to get vaccinated, Where to access the vaccine, Why it matters-designed particularly for cancer survivors.
| Study group | Role | What they receive |
|---|---|---|
| HPV Vaccination Education | Other | Microvideos are designed to be <2 minutes long and to address key information on a topic in an engaging and concise manner. HPV vaccine education will be provided to unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention. Receives: Behavioral: Microvideos: HPV Vaccination Education |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of Microvideo education
Feasibility will be defined as ≥80% of participants completing the intervention and study surveys.
Measured: up to 4 weeks
Secondary outcomes (3)
Acceptability of Microvideo Education
Acceptability will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform.
Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform.
Measured: up to 4 weeks
Satisfaction Acceptability of Microvideo Education
Satisfaction will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform.
Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform.
Measured: up to 4 weeks
HPV Vaccine Intention
To assess HPV vaccine intention among unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention.
This outcome measure will report the count of participants who intended to receive the HPV Vaccine after the microvideo education.
Measured: up to 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2026
- Study start27 Oct 2026 (estimated)
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HPV VaccinationStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 55 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- Prevent Cancer Foundation, Huntsman Cancer Institute
- Responsible party
- Sponsor
- Investigators
- Echo Warner, MPH, PhD, SB, Principal investigator, Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07648953
- Sponsor's protocol ID
- 198894
- Status last verified
- May 2026
- First submitted
- 27 May 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors
- ClinicalTrials.gov ID
- NCT07648953
- Acronym / sponsor ID
- 198894
- Conditions
- HPV Vaccination
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 55 participants (estimated)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Collaborators
- Prevent Cancer Foundation, Huntsman Cancer Institute
- Study start
- 27 Oct 2026 (estimated)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 15 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.
Understanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| HPV Vaccination Education | Other | Behavioral: Microvideos: HPV Vaccination EducationMicrovideos are designed to be <2 minutes long and to address key information on a topic in an engaging and concise manner. HPV vaccine education will be provided to unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention. |
Who may qualify
- Ages
- 18 to 26 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.
- Currently use Facebook or willing to create a Facebook account to use for the duration of the study.
- At the time of enrollment, have not completed all recommended doses of the HPV vaccine.
Key exclusion criteria (3 listed)
- Unable to speak and understand English.
- Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.
- Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Microvideos: HPV Vaccination EducationTo educate survivors of childhood cancers about a key cancer prevention strategy, HPV vaccination. The core microvideos will focus on the 5 Ws of HPV vaccination: Who should get vaccinated, What HPV vaccination protects against, When to get vaccinated, Where to access the vaccine, Why it matters-designed particularly for cancer survivors. | Behavioural | HPV Vaccination Education |
Primary outcome
Feasibility of Microvideo education
Time frame: up to 4 weeks
Feasibility will be defined as ≥80% of participants completing the intervention and study surveys.
3 secondary outcomes
Acceptability of Microvideo Education
Time frame: up to 4 weeks
Satisfaction Acceptability of Microvideo Education
Time frame: up to 4 weeks
HPV Vaccine Intention
Time frame: up to 4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for HPV Vaccination
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Active, not recruitingPhase 4
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
HPV Infection
Active, not recruiting
Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care
Human Papillomavirus Infection
Active, not recruiting
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
Human Papilloma Virus (HPV) Vaccine
Active, not recruitingPhase 3
PREVENT HPV -Related Cancers Trial
HPV Vaccination, Uptake Vaccination
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Echo Warner, MPH, PhD, SB principal investigator
Huntsman Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Microvideos: HPV Vaccination Education in people with HPV Vaccination, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Echo Warner, MPH, PhD, SB (801-244-7040, echo.warner@hci.utah.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of Microvideo education (time frame: up to 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.